Overview
Lobbying Costs
250,000€
Financial year: Jan 2016 - Dec 2016
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
UCB
EU Transparency Register
294359117093-66 First registered on 24 Apr 2015
Goals / Remit
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB).
Main EU files targeted
Engage governments and policymakers worldwide on issues important to UCB to:
• Ensure patients have access to medicines they need
• Provide coverage and reimbursement that reward innovation
• Introduce sound, science-based regulation
• Enable biotechnology research and development (R&D)Address
Head Office
Allée de la Recherche 60
Brussels 1070
BELGIUM -
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
1 FTE (50%)
1 FTE (25%)
People with less than 10% of their time spent on activities covered by the Register are not reportedPerson in charge of EU relations
Mr Didier Malherbe (Head of Public Affairs)
Person with legal responsibility
Mr Jean-Christophe Tellier (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
EFPIA = European Federation of Pharmaceutical Industries and Associations
(http://efpia.eu/)
EBE = European Biopharmaceuticals Entreprises (http://www.ebe-biopharma.eu/)Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2016 - Dec 2016
Lobbying costs for closed financial year
250,000€
EU grant income for closed financial year
501,120 € (Source: Horizon 2020)
Other financial info
funding received from EU institutions: (2015 latest info available)
675179 - TASPPI - TARGETED SMALL-MOLECULE STABILISATION OF
PROTEIN-PROTEIN INTERACTIONS"
675071 - ISOTOPICS - ISOTOPIC LABELING
FOR DRUG INNOVATION"
-
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
None
Other activities
None declared
Meetings
Meetings
None declared